These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23646111)

  • 21. Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients.
    Casado JL; Marín A; Moreno A; Iglesias V; Perez-Elías MJ; Moreno S; Corral I
    J Neurovirol; 2014 Feb; 20(1):54-61. PubMed ID: 24420449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurocognitive functioning of HIV positive children attending the comprehensive care clinic at Kenyatta national hospital: exploring neurocognitive deficits and psychosocial risk factors.
    Musindo O; Bangirana P; Kigamwa P; Okoth R; Kumar M
    AIDS Care; 2018 May; 30(5):618-622. PubMed ID: 29353495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy.
    Marra CM; Lockhart D; Zunt JR; Perrin M; Coombs RW; Collier AC
    Neurology; 2003 Apr; 60(8):1388-90. PubMed ID: 12707454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Higher soluble CD14 levels are associated with lower visuospatial memory performance in youth with HIV.
    Kim-Chang JJ; Donovan K; Loop MS; Hong S; Fischer B; Venturi G; Garvie PA; Kohn J; Rendina HJ; Woods SP; Goodenow MM; Nichols SL; Sleasman JW;
    AIDS; 2019 Dec; 33(15):2363-2374. PubMed ID: 31764101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
    Vibhagool A; Cahn P; Schechter M; Smaill F; Soto-Ramirez L; Carosi G; Montroni M; Pharo CE; Jordan JC; Thomas NE; Pearce G
    Curr Med Res Opin; 2004 Jul; 20(7):1103-14. PubMed ID: 15265255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for neuropsychological health disparities in Black Americans with HIV disease.
    Thompson JL; Beltran-Najera I; Johnson B; Morales Y; Woods SP
    Clin Neuropsychol; 2022 Feb; 36(2):388-413. PubMed ID: 35166174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.
    Paton NI; Stöhr W; Oddershede L; Arenas-Pinto A; Walker S; Sculpher M; Dunn DT
    Health Technol Assess; 2016 Mar; 20(21):1-158. PubMed ID: 26986803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
    Winston A; Puls R; Kerr SJ; Duncombe C; Li PC; Gill JM; Taylor-Robinson SD; Emery S; Cooper DA;
    HIV Med; 2012 Apr; 13(4):245-51. PubMed ID: 22151608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy.
    Shanbhag MC; Rutstein RM; Zaoutis T; Zhao H; Chao D; Radcliffe J
    Arch Pediatr Adolesc Med; 2005 Jul; 159(7):651-6. PubMed ID: 15996999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower Interferon Regulatory Factor-8 Expression in Peripheral Myeloid Cells Tracks With Adverse Central Nervous System Outcomes in Treated HIV Infection.
    D'Antoni ML; Kallianpur KJ; Premeaux TA; Corley MJ; Fujita T; Laws EI; Ogata-Arakaki D; Chow DC; Khadka VS; Shikuma CM; Ndhlovu LC
    Front Immunol; 2019; 10():2789. PubMed ID: 31849969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile.
    Métral M; Darling K; Locatelli I; Nadin I; Santos G; Brugger P; Kovari H; Cusini A; Gutbrod K; Tarr PE; Calmy A; Lecompte TD; Assal F; Monsch A; Kunze U; Stoeckle M; Schwind M; Schmid P; Pignatti R; Di Benedetto C; Du Pasquier R; Cavassini M; ;
    HIV Med; 2020 Jan; 21(1):30-42. PubMed ID: 31589807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy.
    Giancola ML; Lorenzini P; Balestra P; Larussa D; Baldini F; Corpolongo A; Narciso P; Bellagamba R; Tozzi V; Antinori A
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):332-7. PubMed ID: 16540934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.
    Tozzi V; Balestra P; Galgani S; Narciso P; Ferri F; Sebastiani G; D'Amato C; Affricano C; Pigorini F; Pau FM; De Felici A; Benedetto A
    AIDS; 1999 Oct; 13(14):1889-97. PubMed ID: 10513647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy.
    Garvey LJ; Yerrakalva D; Winston A
    AIDS Res Hum Retroviruses; 2009 Aug; 25(8):765-9. PubMed ID: 19678764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial.
    Winston A; Stöhr W; Antinori A; Amieva H; Perré P; De Wit S; Reynes J; Gompels M; dʼArminio Monforte A; Gatell JM; Grarup J; Pozniak A; Babiker A; Raffi F; Richert L;
    J Acquir Immune Defic Syndr; 2017 Feb; 74(2):185-192. PubMed ID: 27749603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.
    Ciccarelli N; Fabbiani M; Colafigli M; Trecarichi EM; Silveri MC; Cauda R; Murri R; De Luca A; Di Giambenedetto S
    Antivir Ther; 2013; 18(2):153-60. PubMed ID: 23486721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive reserve and neuropsychological functioning in older HIV-infected people.
    Milanini B; Ciccarelli N; Fabbiani M; Limiti S; Grima P; Rossetti B; Visconti E; Tamburrini E; Cauda R; Di Giambenedetto S
    J Neurovirol; 2016 Oct; 22(5):575-583. PubMed ID: 26965299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
    Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.